DK3121198T3 - Rekombinant human g-csf-dimer og anvendelse deraf til behandlingen af neurologiske sygdomme - Google Patents
Rekombinant human g-csf-dimer og anvendelse deraf til behandlingen af neurologiske sygdomme Download PDFInfo
- Publication number
- DK3121198T3 DK3121198T3 DK16185991T DK16185991T DK3121198T3 DK 3121198 T3 DK3121198 T3 DK 3121198T3 DK 16185991 T DK16185991 T DK 16185991T DK 16185991 T DK16185991 T DK 16185991T DK 3121198 T3 DK3121198 T3 DK 3121198T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- recombinant human
- neurological diseases
- csf dimer
- csf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101816235A CN102260343A (zh) | 2010-05-25 | 2010-05-25 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| EP11786091.6A EP2576624B1 (en) | 2010-05-25 | 2011-05-25 | Recombinant human g-csf dimer and use thereof for the treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3121198T3 true DK3121198T3 (da) | 2019-10-28 |
Family
ID=45003325
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11786091.6T DK2576624T3 (da) | 2010-05-25 | 2011-05-25 | Rekombinant human g-csf-dimer og anvendelse deraf til behandlingen af neurologiske sygdomme |
| DK16185991T DK3121198T3 (da) | 2010-05-25 | 2011-05-25 | Rekombinant human g-csf-dimer og anvendelse deraf til behandlingen af neurologiske sygdomme |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11786091.6T DK2576624T3 (da) | 2010-05-25 | 2011-05-25 | Rekombinant human g-csf-dimer og anvendelse deraf til behandlingen af neurologiske sygdomme |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8557546B2 (da) |
| EP (2) | EP2576624B1 (da) |
| JP (1) | JP6114186B2 (da) |
| CN (3) | CN102260343A (da) |
| AU (1) | AU2011257734B2 (da) |
| CA (1) | CA2800688C (da) |
| DK (2) | DK2576624T3 (da) |
| ES (2) | ES2611151T3 (da) |
| HU (1) | HUE031872T2 (da) |
| PL (1) | PL2576624T3 (da) |
| PT (1) | PT2576624T (da) |
| WO (1) | WO2011147319A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637637B2 (en) * | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
| CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术（上海）有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| CN102380090A (zh) * | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | G-csf二聚体在治疗嗜中性粒细胞减少症中的应用 |
| EP2737905B1 (en) * | 2011-07-25 | 2019-09-11 | Generon (Shanghai) Corporation Ltd. | Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases |
| CN103717614A (zh) * | 2011-08-09 | 2014-04-09 | 普罗法尔马封闭式股份公司 | 重组蛋白质的衍生物、粒细胞集落刺激因子的同多聚体及其制备方法 |
| US9359374B2 (en) * | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
| LT6161B (lt) * | 2013-09-27 | 2015-06-25 | Uab Profarma | Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas |
| CN113480667B (zh) * | 2021-08-17 | 2023-03-28 | 长春萤火虫生物科技有限公司 | 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用 |
| WO2024037633A2 (en) | 2022-08-19 | 2024-02-22 | Evive Biotechnology (Shanghai) Ltd | Formulations comprising g-csf and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3954004B2 (ja) | 1991-12-26 | 2007-08-08 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
| EP0807181A1 (en) | 1995-02-03 | 1997-11-19 | G.D. Searle & Co. | NOVEL c-MPL LIGANDS |
| US6551799B2 (en) | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1131333B1 (en) | 1998-10-26 | 2010-06-02 | Wyeth a Corporation of the State of Delaware | ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF |
| US6274710B1 (en) | 1998-10-26 | 2001-08-14 | Ludwig Institute For Cancer Research | Antibodies which specifically bind T Cell inducible factors (TIFs) |
| US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
| US7754855B1 (en) * | 1999-07-13 | 2010-07-13 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
| GB0024442D0 (en) | 2000-10-05 | 2000-11-22 | Isis Innovation | Genetic factors affecting the outcome of viral infections |
| EP1334127A1 (en) * | 2000-11-02 | 2003-08-13 | Maxygen Aps | Single-chain multimeric polypeptides |
| US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| EP1572936A2 (en) * | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| EP1817047B1 (en) | 2004-11-05 | 2012-02-08 | Northwestern University | Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
| CN100515491C (zh) | 2005-01-04 | 2009-07-22 | 健能隆医药技术（上海）有限公司 | 白介素-22的医药用途 |
| US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
| WO2008137571A1 (en) | 2007-05-01 | 2008-11-13 | Florida Atlantic University | Methods of treating neurodegenerative diseases |
| WO2008147534A1 (en) | 2007-05-22 | 2008-12-04 | Maxygen Holdings Ltd. | Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
| ES2623925T3 (es) * | 2007-05-30 | 2017-07-12 | Postech Academy-Industry- Foundation | Proteínas de fusión de inmunoglobulina |
| CN101827857A (zh) | 2007-08-03 | 2010-09-08 | 埃斯特瑞恩有限公司 | 粒细胞集落刺激因子 |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| ES2662845T3 (es) | 2007-11-07 | 2018-04-10 | Genentech, Inc. | IL-22 para su uso en el tratamiento de trastornos microbianos |
| BRPI0916515B8 (pt) | 2008-07-23 | 2021-07-27 | Ambrx Inc | polipeptídeo de fator estimulante de colônias de granulócitos bovino (bg-csf), formulação farmacêutica e composição compreendendo o mesmo |
| CA2788096A1 (en) | 2010-01-13 | 2011-07-21 | Amgen Inc. | Il-22-fc and hepcidin activity |
| LT2010013A (lt) | 2010-02-10 | 2011-08-25 | Uab Profarma, , | Biologiškai aktyvių granulocitų kolonijas stimuliuojančio faktoriaus darinių išskyrimo ir gryninimo būdas |
| LT2010012A (lt) | 2010-02-10 | 2011-08-25 | Uab Profarma, , | Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme |
| CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术（上海）有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| CN102380090A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | G-csf二聚体在治疗嗜中性粒细胞减少症中的应用 |
| EP2737905B1 (en) | 2011-07-25 | 2019-09-11 | Generon (Shanghai) Corporation Ltd. | Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases |
-
2010
- 2010-05-25 CN CN2010101816235A patent/CN102260343A/zh active Pending
-
2011
- 2011-05-23 US US13/114,035 patent/US8557546B2/en active Active
- 2011-05-25 CN CN201510112334.2A patent/CN104710535B/zh active Active
- 2011-05-25 PL PL11786091T patent/PL2576624T3/pl unknown
- 2011-05-25 DK DK11786091.6T patent/DK2576624T3/da active
- 2011-05-25 HU HUE11786091A patent/HUE031872T2/en unknown
- 2011-05-25 ES ES11786091.6T patent/ES2611151T3/es active Active
- 2011-05-25 CN CN201180025773.XA patent/CN102906120B/zh active Active
- 2011-05-25 DK DK16185991T patent/DK3121198T3/da active
- 2011-05-25 CA CA2800688A patent/CA2800688C/en active Active
- 2011-05-25 ES ES16185991T patent/ES2750730T3/es active Active
- 2011-05-25 AU AU2011257734A patent/AU2011257734B2/en active Active
- 2011-05-25 EP EP11786091.6A patent/EP2576624B1/en active Active
- 2011-05-25 WO PCT/CN2011/074678 patent/WO2011147319A1/en active Application Filing
- 2011-05-25 EP EP16185991.3A patent/EP3121198B1/en active Active
- 2011-05-25 PT PT117860916T patent/PT2576624T/pt unknown
- 2011-05-25 JP JP2013511527A patent/JP6114186B2/ja active Active
-
2013
- 2013-08-30 US US14/014,413 patent/US9273108B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011257734B2 (en) | 2015-06-11 |
| EP3121198A1 (en) | 2017-01-25 |
| EP2576624A4 (en) | 2013-11-13 |
| ES2611151T3 (es) | 2017-05-05 |
| CN102260343A (zh) | 2011-11-30 |
| EP3121198B1 (en) | 2019-08-14 |
| CA2800688C (en) | 2018-05-15 |
| CN104710535A (zh) | 2015-06-17 |
| EP2576624B1 (en) | 2016-08-31 |
| CA2800688A1 (en) | 2011-12-01 |
| JP6114186B2 (ja) | 2017-04-12 |
| US20140004076A1 (en) | 2014-01-02 |
| WO2011147319A1 (en) | 2011-12-01 |
| US9273108B2 (en) | 2016-03-01 |
| CN102906120B (zh) | 2015-03-04 |
| EP2576624A1 (en) | 2013-04-10 |
| US8557546B2 (en) | 2013-10-15 |
| CN104710535B (zh) | 2018-10-16 |
| ES2750730T3 (es) | 2020-03-26 |
| AU2011257734A1 (en) | 2012-12-20 |
| US20110293554A1 (en) | 2011-12-01 |
| PL2576624T3 (pl) | 2017-02-28 |
| CN102906120A (zh) | 2013-01-30 |
| DK2576624T3 (da) | 2016-11-14 |
| HUE031872T2 (en) | 2017-08-28 |
| PT2576624T (pt) | 2016-10-31 |
| JP2013530148A (ja) | 2013-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3121198T3 (da) | Rekombinant human g-csf-dimer og anvendelse deraf til behandlingen af neurologiske sygdomme | |
| CY2017019I1 (el) | Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| HK1200740A1 (en) | Combination therapy of antibodies against human csf-1r and uses thereof csf-1r | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| CY2014006I2 (el) | Μεθοδοι θεραπευτικης αγωγης χρησιμοποιωντας γλυκοπεγκυλιωμενο g-csf | |
| DK2507211T3 (da) | Apoptosefremkaldende midler til behandling af cancer og immun- og autoimmun-sygdomme | |
| DK2511264T3 (da) | Apoptose-inducerende midler til behandling af cancer og immunsygdomme og autoimmune sygdomme | |
| ZA201301601B (en) | Treatment of diseases | |
| HK1199401A1 (en) | Pharmaceutical formulations and the use thereof for the treatment of peanut allergy | |
| EP2613786A4 (en) | TREATMENT OF DISEASES | |
| DK2538986T3 (da) | Intraartikulært supplement til anvendelse til behandling af ledsygdomme og -skader | |
| BR112014028413A2 (pt) | usos terapêuticos de proteínas do fator de crescimento de fibroblastos 21 . | |
| HK1184370A1 (zh) | 用於治療疼痛的藥物組合 | |
| IL239629A0 (en) | History of benzylideneguanidine and therapeutic use for the treatment of diseases resulting from misfolding of proteins | |
| EP2949651A4 (en) | SUBSTITUTED BENZOTHIAZOLES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF HUMAN DISEASES | |
| DK2892556T3 (da) | Sammensætninger og fremgangsmåder til behandling af sygdomme | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| DK3485883T3 (da) | Metoder til behandling af øjensygdomme forbundet med betændelse og vaskulær spredning | |
| IL238775A0 (en) | Purification of human recombinant galactocerebralsidase beta-galactosidase | |
| PL2854748T3 (pl) | Kompozycja farmaceutyczna do leczenia zapalenia skóry i powiązanych syndromów | |
| PT2555790T (pt) | USO TERAPÊUTICO DA PROTEÍNA DE ß MICROGLOBULINA | |
| DK2912173T3 (da) | Fremgangsmåde til fremstilling og oprensning af rekombinant humant oncostatin-m-protein | |
| TH1401001121B (th) | เก้าอี้ออร์โทพีดิกส์สำหรับการรักษาและการป้องกันโรคกระดูกสันหลัง |